| Business Summary | | Epoch
Biosciences,
Inc.,
formerly
Epoch
Pharmaceuticals,
Inc.,
is
developing
and
commercializing
proprietary
technologies
to
enhance
the
study
of
genes.
Its
scientists
are
applying
their
expertise
in
nucleic
acid
chemistry
to
develop
products
that
improve
methods
of
studying
the
genetic
sequence
(genomes)
of
humans,
animals
and
plants.
The
Company
is
utilizing
its
knowledge
in
DNA
chemistry
to
design,
synthesize
and
modify
synthetic
DNA
strands
(probes)
that
selectively
bind
to
the
gene
being
studied.
Using
its
DNA
technology,
the
Company
is
developing
molecular
tools
and
chemical
compounds
for
improved
genetic
analysis.
Epoch
has
adapted
its
chemical
compounds
and
techniques
to
genetic
analysis
systems
developed
by
Applied
Biosystems
and
Third
Wave
Technologies.
Applications
include
the
detection
of
infectious
diseases,
diagnosis
of
inheritable
diseases
through
prenatal
testing
and
screening
populations
to
identify
genetic
markers
that
correlate
with
disease
risk
or
drug
response. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Epoch
Biosciences,
Inc.
is
a
biomedical
company
utilizing
nucleoside
and
nucleotide
chemistry
to
develop
molecular
tools
for
genetic
analysis,
providing
products
and
techniques
for
high
throughput
genetic
sequence
anaylsis.
For
the
six
months
ended
6/30/01,
revenues
totaled
$3.3
million,
up
from
$239
thousand.
Net
loss
rose
5%
to
$2.5
million.
Results
reflect
increased
chemical
intermediate
sales,
offset
by
lower
profit
margins
due
to
product
mix
and
capacity
utilization. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Fred Craves, Ph.D., 55 Chairman | $59K | -- | William Gerber, M.D., 54 CEO,
Director | 331K | -- | Sanford Zweifach, 45 Pres,
Sec., Director | 135K | $82K | Bert Hogue, 43 CFO,
VP-Fin. | -- | -- | Merl Hoekstra, Ph.D., 41 VP,
Corp. Devel. | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|